Successful Febuxostat Desensitization in a Patient with Febuxostat Hypersensitivity: A Malaysian Experience
Overview
Overview
Journal
SAGE Open Med Case Rep
Publisher
Sage Publications
Specialty
General Medicine
Date
2018 Jan 11
PMID
29318019
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Over the years, allopurinol has been widely used as the preferred choice of urate lowering therapy in patients with gout. However, its role in patients with renal impairment is limited; and adverse reactions are well documented. Febuxostat, a newer oral non-purine xanthine oxidase inhibitor has been proven in several trials to be more effective and tolerable compared to allopurinol and may be used in patients with renal impairment. Here, we describe a case of successful febuxostat desensitization in a patient with a history of allopurinol- and febuxostat-induced adverse cutaneous reaction, as well as the protocol utilized.
References
1.
Chohan S
. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011; 38(9):1957-9.
DOI: 10.3899/jrheum.110092.
View
2.
Abeles A
. Febuxostat hypersensitivity. J Rheumatol. 2012; 39(3):659.
DOI: 10.3899/jrheum.111161.
View
3.
Di Paolo C, Minetti S, Mineni M, Inverardi S, Lodi Rizzini F, Cinquini M
. Desensitization to febuxostat: report of two cases. J Allergy Clin Immunol Pract. 2015; 3(4):633-6.
DOI: 10.1016/j.jaip.2015.01.022.
View
4.
Schumacher Jr H, Becker M, Wortmann R, MacDonald P, Hunt B, Streit J
. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59(11):1540-8.
DOI: 10.1002/art.24209.
View
5.
Becker M, Schumacher Jr H, Wortmann R, MacDonald P, Eustace D, Palo W
. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450-61.
DOI: 10.1056/NEJMoa050373.
View